2019 Q1 Form 10-Q Financial Statement
#000156459019015449 Filed on May 03, 2019
Income Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| Revenue | $12.47M | $15.96M |
| YoY Change | -21.85% | 133.56% |
| Cost Of Revenue | $430.0K | $17.00K |
| YoY Change | 2429.41% | |
| Gross Profit | $12.04M | $15.94M |
| YoY Change | -24.46% | |
| Gross Profit Margin | 96.55% | 99.89% |
| Selling, General & Admin | $60.28M | $34.90M |
| YoY Change | 72.72% | 71.92% |
| % of Gross Profit | 500.61% | 218.95% |
| Research & Development | $122.6M | $97.10M |
| YoY Change | 26.3% | 76.55% |
| % of Gross Profit | 1018.52% | 609.16% |
| Depreciation & Amortization | $3.780M | $4.020M |
| YoY Change | -5.97% | 41.55% |
| % of Gross Profit | 31.39% | 25.22% |
| Operating Expenses | $182.9M | $132.6M |
| YoY Change | 37.96% | 72.76% |
| Operating Profit | -$171.2M | -$116.6M |
| YoY Change | 46.77% | 66.82% |
| Interest Expense | $10.10M | $1.388M |
| YoY Change | 627.81% | -10.8% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$3.389M | $115.0K |
| YoY Change | -3046.96% | -132.39% |
| Pretax Income | -$164.5M | -$115.1M |
| YoY Change | 42.85% | 67.55% |
| Income Tax | -$15.00K | |
| % Of Pretax Income | ||
| Net Earnings | -$164.4M | -$115.1M |
| YoY Change | 42.84% | 67.55% |
| Net Earnings / Revenue | -1318.63% | -721.48% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$2.989M | -$2.307M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 54.95M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.731B | $1.122B |
| YoY Change | 54.31% | 76.88% |
| Cash & Equivalents | $221.7M | $470.4M |
| Short-Term Investments | $1.509B | $665.0M |
| Other Short-Term Assets | $39.40M | $42.50M |
| YoY Change | -7.29% | 1193.76% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $3.800M | $6.276M |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $1.365B | $1.164B |
| YoY Change | 17.26% | 74.45% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $298.6M | $204.2M |
| YoY Change | 46.23% | 12.38% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $408.9M | $444.8M |
| YoY Change | -8.07% | 168.28% |
| Other Assets | $40.60M | $24.60M |
| YoY Change | 65.04% | -1.2% |
| Total Long-Term Assets | $773.6M | $702.7M |
| YoY Change | 10.09% | 73.38% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $1.365B | $1.164B |
| Total Long-Term Assets | $773.6M | $702.7M |
| Total Assets | $2.139B | $1.867B |
| YoY Change | 14.56% | 74.04% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $30.20M | $12.00M |
| YoY Change | 151.67% | 36.36% |
| Accrued Expenses | $63.00M | $60.10M |
| YoY Change | 4.83% | 60.27% |
| Deferred Revenue | $11.49M | $45.34M |
| YoY Change | -74.66% | |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | $1.000M |
| YoY Change | -100.0% | |
| Total Short-Term Liabilities | $146.7M | $107.8M |
| YoY Change | 36.09% | 48.48% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $154.5M |
| YoY Change | -100.0% | 4.67% |
| Other Long-Term Liabilities | $219.8M | $34.30M |
| YoY Change | 540.82% | -7.3% |
| Total Long-Term Liabilities | $219.8M | $188.8M |
| YoY Change | 16.42% | 2.28% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $146.7M | $107.8M |
| Total Long-Term Liabilities | $219.8M | $188.8M |
| Total Liabilities | $366.5M | $296.6M |
| YoY Change | 23.57% | 15.32% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$943.2M | |
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $1.772B | $1.570B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $2.139B | $1.867B |
| YoY Change | 14.56% | 74.04% |
Cashflow Statement
| Concept | 2019 Q1 | 2018 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$164.4M | -$115.1M |
| YoY Change | 42.84% | 67.55% |
| Depreciation, Depletion And Amortization | $3.780M | $4.020M |
| YoY Change | -5.97% | 41.55% |
| Cash From Operating Activities | -$154.2M | -$108.8M |
| YoY Change | 41.66% | 44.52% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $19.32M | $7.452M |
| YoY Change | 159.27% | -71.36% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$17.59M | -$257.3M |
| YoY Change | -93.16% | -1292.72% |
| Cash From Investing Activities | -$36.91M | -$264.7M |
| YoY Change | -86.06% | 5848.88% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $48.70M | |
| YoY Change | 1501.97% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $10.22M | 71.68M |
| YoY Change | -85.74% | 324.88% |
| NET CHANGE | ||
| Cash From Operating Activities | -$154.2M | -108.8M |
| Cash From Investing Activities | -$36.91M | -264.7M |
| Cash From Financing Activities | $10.22M | 71.68M |
| Net Change In Cash | -$180.8M | -301.9M |
| YoY Change | -40.09% | 380.07% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$154.2M | -$108.8M |
| Capital Expenditures | $19.32M | $7.452M |
| Free Cash Flow | -$173.5M | -$116.3M |
| YoY Change | 49.2% | 14.75% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | blue |
Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
|
19449000 | |
| CY2018Q4 | blue |
Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
|
13931000 | |
| CY2019Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
11490000 | |
| CY2019Q1 | blue |
Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
|
11242000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
184618000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
17566000 | |
| CY2018Q4 | blue |
Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
|
33349000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
168200000 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
12471000 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
15957000 | |
| CY2019Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
430000 | |
| CY2018Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
17000 | |
| CY2019Q1 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
blue:LicenseAndRoyaltyMember | |
| CY2018Q1 | us-gaap |
Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
|
blue:LicenseAndRoyaltyMember | |
| CY2018Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
4020000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
32341000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
22995000 | |
| CY2019Q1 | us-gaap |
Available For Sale Equity Securities Gross Unrealized Loss
AvailableForSaleEquitySecuritiesGrossUnrealizedLoss
|
3085000 | |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
3456000 | |
| CY2018Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-2403000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
12793000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
13486000 | |
| CY2019Q1 | blue |
Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
|
-5374000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
10590000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-737000 | |
| CY2019Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
10102000 | |
| CY2018Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1388000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.99 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.31 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
54957000 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
49923000 | |
| CY2019Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
|
1835000 | |
| CY2018Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities And Pension And Other Postretirement Benefit Plans Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesAndPensionAndOtherPostretirementBenefitPlansArisingDuringPeriodNetOfTax
|
-844000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
1835000 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-844000 | |
| CY2019Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
|
400000 | |
| CY2018Q1 | blue |
Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
|
0 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
9504000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1231000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
32341000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1623432000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
48701000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
19730000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
687000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
22995000 | |
| CY2018Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1570201000 | |
| CY2018Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
2563000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-164446000 | |
| CY2018Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-115126000 | |
| CY2019Q1 | blue |
Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
|
296000 | |
| CY2018Q1 | blue |
Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
|
534000 | |
| CY2019Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
3783000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-21514000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
4541000 | |
| CY2019Q1 | blue |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
3224000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-8672000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-13966000 | |
| CY2019Q1 | blue |
Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
|
1966000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-154154000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-108822000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
19321000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7452000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
381735000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
402413000 | |
| CY2019Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
364143000 | |
| CY2018Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
145140000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-36913000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-264725000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
48701000 | |
| CY2018Q1 | blue |
Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
|
3098000 | |
| CY2018Q1 | us-gaap |
Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
|
106000 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
10223000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
19984000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
10223000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
71677000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-180844000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-301870000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
417099000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
772268000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
236255000 | |
| CY2018Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
470398000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
9302000 | |
| CY2018Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2817000 | |
| CY2019Q1 | blue |
Assets Acquired Under Operating Lease Obligation
AssetsAcquiredUnderOperatingLeaseObligation
|
5500000 | |
| CY2019Q1 | blue |
Tenant Improvements Included In Tenant Improvements Receivables Including Other Current Assets
TenantImprovementsIncludedInTenantImprovementsReceivablesIncludingOtherCurrentAssets
|
8009000 | |
| CY2018Q1 | blue |
Tenant Improvements Included In Tenant Improvements Receivables Including Other Current Assets
TenantImprovementsIncludedInTenantImprovementsReceivablesIncludingOtherCurrentAssets
|
14000 | |
| CY2019Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
100000 | |
| CY2018Q1 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
100000 | |
| CY2019Q1 | us-gaap |
Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
|
blue:ReceivablesAndOtherCurrentAssets | |
| CY2018Q1 | us-gaap |
Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
|
blue:ReceivablesAndOtherCurrentAssets | |
| CY2019Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
14417000 | |
| CY2018Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
13763000 | |
| CY2019Q1 | us-gaap |
Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
| CY2018Q1 | us-gaap |
Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsNoncurrent | |
| CY2019Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Note_to_Condensed"></a><a name="Note_to_Condensed"></a>1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for the treatment of severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s programs in severe genetic diseases include ZYNTEGLO<sup style="font-size:85%; vertical-align:top">TM</sup> (autologous CD34+ cells encoding β<sup style="font-size:85%; vertical-align:top">A-T87Q</sup>-globin gene) as a treatment for transfusion-dependent β-thalassemia, or TDT; its LentiGlobin<sup style="font-size:85%; vertical-align:top">®</sup> product candidate as a treatment for sickle cell disease, or SCD; and its Lenti-D<sup style="font-size:85%; vertical-align:top">TM</sup> product candidate as a treatment for cerebral adrenoleukodystrophy, or CALD. In the second half of 2018, the Company filed a marketing authorization application with the European Medicines Agency, or EMA, for ZYNTEGLO (formerly referred to as LentiGlobin for TDT) for the treatment of patients 12 years and older with TDT who do not have a β<sup style="font-size:85%; vertical-align:top">0</sup>/β<sup style="font-size:85%; vertical-align:top">0</sup> genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte-matched related HSC donor is not available. In March 2019, the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion recommending conditional marketing authorization for ZYNTEGLO in Europe. Assuming that the application is conditionally approved, the Company expects to begin commercializing and generating product revenues in the second half of 2019. The Company’s programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Idecabtagene vicleucel, or ide-cel (bb2121), and bb21217, which are product candidates in oncology under the Company’s collaboration arrangement with Celgene Corporation (“Celgene”), are CAR T cell product candidates for the treatment of multiple myeloma. Please <font style="color:#000000;">refer</font> to Note 9, “<font style="font-style:italic;">Collaborative arrangements</font>” for further discussion of the Company’s collaboration with Celgene<font style="color:#000000;">.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the Company had cash, cash equivalents and marketable securities of $1.73 billion. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund current planned operations for at least the next twelve months. </p> | |
| CY2019Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the <font style="color:#000000;">reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially</font> from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: subsequent fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p> | |
| CY2018Q4 | blue |
Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
|
3011000 | |
| CY2019Q1 | us-gaap |
Marketable Securities
MarketableSecurities
|
1509028000 | |
| CY2019Q1 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1992-04-16 | |
| CY2019Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
1730000000 | |
| CY2019Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2019Q1 | us-gaap |
Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
|
20017000 | |
| CY2018Q4 | us-gaap |
Equity Securities Fv Ni Cost
EquitySecuritiesFvNiCost
|
20017000 | |
| CY2018Q4 | blue |
Equity Securities Unrealized Gain
EquitySecuritiesUnrealizedGain
|
2150000 | |
| CY2019Q1 | blue |
Equity Securities Unrealized Loss
EquitySecuritiesUnrealizedLoss
|
934000 | |
| CY2019Q1 | us-gaap |
Equity Securities Fv Ni
EquitySecuritiesFvNi
|
19083000 | |
| CY2018Q4 | us-gaap |
Equity Securities Fv Ni
EquitySecuritiesFvNi
|
22167000 | |
| CY2019Q1 | blue |
Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
|
1509696000 | |
| CY2018Q4 | blue |
Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
|
1488746000 | |
| CY2019Q1 | blue |
Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
|
1685000 | |
| CY2018Q4 | blue |
Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
|
3113000 | |
| CY2019Q1 | blue |
Marketable Securities Unrealized Loss
MarketableSecuritiesUnrealizedLoss
|
2353000 | |
| CY2018Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
1488848000 | |
| CY2019Q1 | us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
90 days or less | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | |
| CY2018Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
189200000 | |
| CY2018Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
787500000 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
411600000 | |
| CY2018Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
315300000 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
100000 | |
| CY2018Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
900000 | |
| CY2019Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
1300000 | |
| CY2018Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
2100000 | |
| CY2019Q1 | us-gaap |
Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
|
0 | |
| CY2018Q4 | us-gaap |
Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
|
0 | |
| CY2019Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
140918000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
275798000 | |
| CY2019Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
26888000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
29176000 | |
| CY2019Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
16404000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
28567000 | |
| CY2019Q1 | blue |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
12125000 | |
| CY2018Q4 | blue |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
21618000 | |
| CY2019Q1 | blue |
Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
|
14724000 | |
| CY2018Q4 | blue |
Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
|
11891000 | |
| CY2019Q1 | blue |
Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
|
323000 | |
| CY2018Q4 | blue |
Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
|
7739000 | |
| CY2019Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1906000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1830000 | |
| CY2018Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
1424000 | |
| CY2019Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
30670000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
26324000 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
127300000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
125800000 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
8483000 | ||
| us-gaap |
Lease Cost
LeaseCost
|
8483000 | ||
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7946000 | ||
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y8M12D | |
| CY2019Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0664 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
21286000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
32093000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
32480000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
27632000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
28033000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
98151000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
239675000 | |
| CY2019Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
53909000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
185766000 | |
| CY2019Q1 | blue |
Lessee Operating Lease Lease Not Yet Commenced Minimum Lease Payments
LesseeOperatingLeaseLeaseNotYetCommencedMinimumLeasePayments
|
18000000 | |
| CY2019Q1 | blue |
Deferred Revenue Released
DeferredRevenueReleased
|
8700000 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
300000 | |
| CY2018Q1 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
185.00 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
48700000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
|
2200000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
|
2000000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2400000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
32341000 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
22995000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4643000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1085000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
189000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
155000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5384000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2372000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
5382000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
108.56 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
135.53 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
50.31 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
136.45 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
115.84 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
82.62 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
115.85 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
9500000 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6527000 | |
| CY2018Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5372000 |
